Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...

Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

Patients with Spinal Muscular Atrophy (SMA) are hopeful of getting access to generic versions of Roche’s patented drug ...

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Shareholders approved all proposals of the Board of Directors Severin Schwan was re-elected as Chairman of the Board of ...

OBT has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment.

Amid Trump’s dismantling of DEI, Roche wiped diversity targets from the website of its US subsidiary, Genentech, in mid-February. Basel-based competitor Novartis also said this week it was getting rid ...